Hims & Hers Health, Inc. (HIMS): who owns it and who trades it
As of Nov 16, 2026, HIMS insiders reported 45 open-market sales worth $19.3M and 1 purchase worth $1.2M in the last 12 months, with 99% of the sale value made under pre-set 10b5-1 plans. The largest seller was Oluyemi Okupe (CFO), with $9.7M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Hims & Hers Health
From the latest filingsOverall: more buying than selling. Funds and famous investors mostly bought. Insiders was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns HIMS
507 funds and institutions reported HIMS shares worth $5.7B at the end of Q2 2026. The largest holder is BlackRock, Inc. with $995M.
10 largest owners, by value
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 28.70M | – | $995M | +9% |
| Vanguard Portfolio Management LLC | 10.56M | – | $366M | +4% |
| Vanguard Capital Management LLC | 9.54M | – | $331M | +2% |
| State Street Corp | 8.15M | – | $282M | +9% |
| California State Teachers Retirement System | 8.00M | – | $231M | +3405% |
| Morgan Stanley | 7.15M | – | $248M | -20% |
| Divisadero Street Capital Management, LP | 6.01M | – | $208M | +1179% |
| Geode Capital Management, LLC | 5.68M | – | $197M | +9% |
| Goldman Sachs Group Inc | 5.17M | – | $179M | +111% |
| JPMorgan Chase & Co | 4.77M | – | $159M | – |
| FMR LLC (Fidelity) | 4.32M | – | $150M | – |
| Marshall Wace, LLP | 4.22M | – | $146M | +482% |
| UBS Group AG | 2.66M | – | $92.3M | -36% |
| Northern Trust Corp | 2.59M | – | $89.9M | +6% |
| Charles Schwab Investment Management Inc | 2.45M | – | $85.1M | +4% |
| Sixth Street Partners Management Company, L.P. | 2.45M | – | $85.1M | – |
| State of Michigan Retirement System | 2.35M | – | $81.3M | +0% |
| Bank of America Corp | 2.31M | – | $80.2M | -47% |
| Principal Financial Group Inc | 1.67M | – | $57.8M | +30% |
| Vanguard Fiduciary Trust Co | 1.52M | – | $52.8M | +5% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, HIMS insiders reported $1.2M of open-market purchases and $19.3M of sales. 99% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 28, 2026 | Soleil Boughton | Chief Legal Officer | Sale plan | 3,462 | $27.60 | $95.6K | Form 4 |
| Oct 14, 2026 | Soleil Boughton | Chief Legal Officer | Sale plan | 3,461 | $29.06 | $101K | Form 4 |
| Oct 1, 2026 | Oluyemi Okupe | CFO | Sale plan | 2,000 | $29.70 | $59.4K | Form 4 |
| Sep 30, 2026 | Soleil Boughton | Chief Legal Officer | Sale plan | 3,461 | $29.17 | $101K | Form 4 |
| Sep 22, 2026 | Oluyemi Okupe | CFO | Sale plan | 29,277 | $29.95 | $877K | Form 4 |
| Sep 17, 2026 | Oluyemi Okupe | CFO | Sale plan | 12,313 | $28.82 | $355K | Form 4 |
| Sep 16, 2026 | Soleil Boughton | Chief Legal Officer | Sale plan | 6,236 | $27.86 | $174K | Form 4 |
| Sep 15, 2026 | Michael Chi | Chief Operating Officer | Sale plan | 14,027 | $28.39 | $398K | Form 4 |
| Sep 15, 2026 | Mohamed Elshenawy | CTO | Sale plan | 7,954 | $28.39 | $226K | Form 4 |
| Sep 2, 2026 | Soleil Boughton | Chief Legal Officer | Sale plan | 3,458 | $28.33 | $98K | Form 4 |
| Aug 19, 2026 | Oluyemi Okupe | CFO | Sale plan | 4,938 | $29.99 | $148K | Form 4 |
| Aug 19, 2026 | Soleil Boughton | Chief Legal Officer | Sale plan | 25,111 | $27.55 | $692K | Form 4 |
| Aug 18, 2026 | Deborah M. Autor | Director | Sale plan | 16,773 | $27.85 | $467K | Form 4 |
| Aug 17, 2026 | Oluyemi Okupe | CFO | Sale plan | 9,388 | $27.89 | $262K | Form 4 |
| Jul 17, 2026 | Oluyemi Okupe | CFO | Sale plan | 7,163 | $31.99 | $229K | Form 4 |
| Jul 6, 2026 | Oluyemi Okupe | CFO | Sale plan | 7,163 | $36.49 | $261K | Form 4 |
| Jun 22, 2026 | Oluyemi Okupe | CFO | Sale plan | 18,197 | $34.03 | $619K | Form 4 |
| Jun 18, 2026 | Oluyemi Okupe | CFO | Sale plan | 55,383 | $35.09 | $1.9M | Form 4 |
| Jun 18, 2026 | Patrick Harrison Carroll | Chief Medical Officer | Sale plan | 23,726 | $35.00 | $830K | Form 4 |
| Jun 17, 2026 | Michael Chi | Chief Operating Officer | Sale plan | 14,027 | $31.50 | $442K | Form 4 |
| Jun 17, 2026 | Irene Becklund | PAO | Sale plan | 4,490 | $31.50 | $141K | Form 4 |
| Jun 17, 2026 | Mohamed Elshenawy | CTO | Sale plan | 30,040 | $31.50 | $946K | Form 4 |
| Jun 16, 2026 | Irene Becklund | PAO | Sale plan | 7,573 | $30.25 | $229K | Form 4 |
| May 26, 2026 | David B Wells | Director | Purchase | 48,400 | $24.24 | $1.2M | Form 4 |
| May 18, 2026 | Oluyemi Okupe | CFO | Sale plan | 7,950 | $23.64 | $188K | Form 4 |
| Apr 20, 2026 | Soleil Boughton | Chief Legal Officer | Sale plan | 9,463 | $30.00 | $284K | Form 4 |
| Apr 20, 2026 | Oluyemi Okupe | CFO | Sale plan | 19,645 | $29.96 | $589K | Form 4 |
| Apr 17, 2026 | Oluyemi Okupe | CFO | Sale plan | 18,005 | $27.83 | $501K | Form 4 |
| Apr 16, 2026 | Oluyemi Okupe | CFO | Sale plan | 36,922 | $25.90 | $956K | Form 4 |
| Apr 6, 2026 | Oluyemi Okupe | CFO | Sale plan | 3,975 | $19.98 | $79.4K | Form 4 |
| Mar 20, 2026 | Oluyemi Okupe | CFO | Sale plan | 9,217 | $23.77 | $219K | Form 4 |
| Mar 17, 2026 | Irene Becklund | PAO | Sale plan | 5,529 | $24.69 | $137K | Form 4 |
| Mar 17, 2026 | Soleil Boughton | Chief Legal Officer | Sale plan | 4,812 | $24.69 | $119K | Form 4 |
| Mar 17, 2026 | Michael Chi | Chief Operating Officer | Sale plan | 97,289 | $24.69 | $2.4M | Form 4 |
| Feb 27, 2026 | Soleil Boughton | Chief Legal Officer | Sale plan | 4,651 | $15.21 | $70.7K | Form 4 |
| Feb 3, 2026 | Oluyemi Okupe | CFO | Sale plan | 5,262 | $26.44 | $139K | Form 4 |
| Jan 20, 2026 | Oluyemi Okupe | CFO | Sale plan | 9,067 | $30.34 | $275K | Form 4 |
| Jan 5, 2026 | Oluyemi Okupe | CFO | Sale plan | 9,070 | $33.79 | $306K | Form 4 |
| Dec 22, 2025 | Oluyemi Okupe | CFO | Sale plan | 23,090 | $35.72 | $825K | Form 4 |
| Dec 17, 2025 | Michael Chi | Chief Operating Officer | Sale plan | 13,750 | $36.71 | $505K | Form 4 |
| Dec 17, 2025 | Deborah M. Autor | Director | Sale plan | 7,054 | $36.71 | $259K | Form 4 |
| Dec 17, 2025 | Patrick Harrison Carroll | Director | Sale plan | 10,021 | $36.71 | $368K | Form 4 |
| Dec 17, 2025 | Irene Becklund | PAO | Sale plan | 8,411 | $36.71 | $309K | Form 4 |
| Dec 9, 2025 | Garcia Andrea G Perez | Director | Sale | 2,500 | $39.17 | $97.9K | Form 4 |
| Nov 24, 2025 | Soleil Boughton | Chief Legal Officer | Sale plan | 2,631 | $35.22 | $92.7K | Form 4 |
| Nov 17, 2025 | Oluyemi Okupe | CFO | Sale plan | 23,187 | $36.81 | $854K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Oluyemi Okupe | Chief Financial Officer | – | $9.7M | Oct 1, 2026 |
| Michael Chi | Chief Operating Officer | – | $3.7M | Sep 15, 2026 |
| Soleil Boughton | Chief Legal Officer | – | $1.8M | Oct 28, 2026 |
| Patrick Harrison Carroll | Chief Medical Officer, Director | – | $1.2M | Jun 18, 2026 |
| David B Wells | Director | $1.2M | – | May 26, 2026 |
| Mohamed Elshenawy | CTO | – | $1.2M | Sep 15, 2026 |
| Irene Becklund | PAO | – | $816K | Jun 17, 2026 |
| Deborah M. Autor | Chief Policy Officer, Director | – | $726K | Aug 18, 2026 |
| Garcia Andrea G Perez | Director | – | $97.9K | Dec 9, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
HIMS short interest
51.66M HIMS shares are sold short. Over the last 12 reports the number of shares short went down 18%.
As of Oct 30, 2026, 51.66M HIMS shares were sold short, down 3.4% from the report before. At the average daily volume of 8.84M shares, buying them all back would take about 5.8 trading days (days to cover).
Shares short
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 51.66M | – | -3% | 8.84M | 5.8 |
| Oct 15, 2026 | 53.47M | – | -2% | 10.68M | 5.0 |
| Sep 30, 2026 | 54.77M | – | +3% | 10.41M | 5.3 |
| Sep 15, 2026 | 52.92M | – | -4% | 8.64M | 6.1 |
| Aug 31, 2026 | 54.95M | – | -6% | 12.70M | 4.3 |
| Aug 14, 2026 | 58.67M | – | -6% | 13.08M | 4.5 |
| Jul 31, 2026 | 62.22M | – | +1% | 16.75M | 3.7 |
| Jul 15, 2026 | 61.41M | – | +0% | 13.58M | 4.5 |
| Jun 30, 2026 | 61.17M | – | -7% | 18.92M | 3.2 |
| Jun 15, 2026 | 65.47M | – | +5% | 18.56M | 3.5 |
| May 29, 2026 | 62.61M | – | -1% | 19.91M | 3.1 |
| May 15, 2026 | 63.37M | – | +0% | 25.86M | 2.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded HIMS
Since Nov 17, 2024, 1 member of Congress reported 1 purchase and 0 sales of HIMS. The latest was a purchase by Lisa C. McClain on Aug 4, 2025, reported Sep 12, 2025.
Purchases 1Sales 0
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Aug 4, 2025 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Sep 12, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Hims & Hers Health company events
Hims & Hers Health filed 15 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026LeadershipThe board of directors of Hims & Hers Health, Inc. increased the size of the Board from nine to ten directors and appointed Dr. Andrew Huberman, 51, to fill the newly created directorship, effective immediately. Filing
- Nov 9, 2026AnnouncementHims & Hers Health’s Disclosure Channels To Disseminate Information Investors of the Company and others should note that we announce information to the public about the Company, the products and services available on the Company’s platform, and other updates regarding the Company through a variety… Filing
- Oct 7, 2026LeadershipJonathan M. Franklin commenced employment with Hims & Hers Health, Inc. as chief accounting officer. Filing
- Aug 10, 2026ResultsReleased financial results. Filing
- Jul 17, 2026LeadershipIrene Becklund informed Hims & Hers Health, Inc. of her intention to resign as Chief Accounting Officer and Principal Accounting Officer, effective as of October 9, 2026. Filing
- Jul 1, 2026AgreementXeCare LLC and Apostrophe Pharmacy LLC, subsidiaries of Hims & Hers Health, Inc., entered into a Master Receivables Purchase Agreement with JPMorgan Chase Bank, N.A., as purchaser (in such capacity, the “ Purchaser ”). Filing
- Jun 15, 2026VoteReported shareholder vote results. Filing
- Jun 2, 2026AgreementHims & Hers Health, Inc., as borrower, entered into Amendment No. 3 to the Revolving Credit and Guaranty Agreement, dated as of February 18, 2025 (as amended by that certain Amendment No. 1 to the Revolving Credit and Guaranty Agreement, dated as of June 25, 2025, that certain Amendment No. 2 to… Filing
- May 21, 2026AgreementThe Company issued $402.5 million of Notes. Filing
- May 19, 2026AnnouncementHims & Hers Health, Inc. issued a press release relating to its proposed private offering of Convertible Senior Notes due 2032 to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Filing
- May 11, 2026ResultsReleased financial results. Filing
- Mar 11, 2026AnnouncementShared information with investors. Filing
- Feb 23, 2026ResultsReleased financial results. Filing
- Feb 19, 2026AgreementHims & Hers Health, Inc., Hims, Inc., and Horizon BidCo Pty Ltd ACN 694 778 375, an Australian proprietary company and wholly-owned subsidiary of the Company, entered into a Securities Sale Deed with the sellers party thereto, pursuant to which, among other things, the Sellers agreed to sell and… Filing
- Nov 17, 2025AnnouncementThe Board of Directors of Hims & Hers Health, Inc. authorized and approved a new share repurchase program pursuant to which the Company may repurchase up to $250.0 million of its Class A common stock. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Hims & Hers Health financials
Famous investors that hold HIMS
5 of the 50 well-known investors we track reported holding HIMS in their latest 13F filing. The largest position is Ken Griffin's, worth $14.3M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 479,984 | $14.3M | 0.0% | -43% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 396,003 | $11.8M | 0.1% | +207% |
| Israel Englander · Millennium Management | Q3 2026 | 132,943 | $4M | 0.0% | New |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 82,335 | $2.5M | 0.0% | +1070% |
| Larry Robbins · Glenview Capital Management | Q3 2026 | 19,800 | $590K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named HIMS in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | G1 Execution Services, LLC | 13G/A | 4.8% |
| Nov 16, 2026 | G1 Execution Services, LLC | 13G/A | 4.8% |
| Oct 30, 2026 | Vanguard Capital Management | 13G/A | 5.0% |
| Oct 30, 2026 | Vanguard Capital Management | 13G/A | 5.0% |
Questions about Hims & Hers Health, Inc. (HIMS) stock
Hims & Hers Health runs an online health platform. Customers see licensed providers through the app and get prescriptions and products for hair loss, sexual health, skin care and weight loss. Andrew Dudum co-founded the company and is its chief executive.
Does Andrew Dudum control Hims & Hers?
He holds most of the votes. Hims & Hers has two classes of stock. Class A shares, which trade on the market, carry one vote each. Class V shares carry 175 votes each and are held by trusts linked to Dudum. At the June 2026 annual meeting there were about 222.5 million Class A shares and 8.4 million Class V shares. By that count, the Class V shares alone carried about 87% of the votes.
The two classes vote together. Dudum's say comes mainly from the Class V shares, not from the size of his economic stake.
Have Hims & Hers insiders sold stock?
In the 12 months to November 9, 2026, insiders reported 45 open-market sales worth about $19.3 million. About 99% of the sale value was under pre-set Rule 10b5-1 plans. Chief financial officer Oluyemi Okupe sold about $9.7 million and chief operating officer Michael Chi about $3.7 million.
There was one open-market purchase. Director David Wells bought 48,400 shares, about $1.2 million, on May 26, 2026. See insider buying vs insider selling.
How many Hims & Hers shares are sold short?
As of October 15, 2026, 53.5 million shares were sold short, down 2.4% from the report before. At the average daily volume of 10.7 million shares, it would take about 5 trading days to buy them all back. The number of shares short fell 16% over the last 11 reports. See what short interest is and days to cover.
What board and leadership changes did Hims & Hers report in 2026?
A Form 8-K filed November 9, 2026 says the board grew from nine to ten directors and appointed Dr. Andrew Huberman to the new seat, effective immediately. In October 2026 Jonathan Franklin started as chief accounting officer.
At the end of Q2 2026, 507 funds and institutions reported Hims & Hers shares. BlackRock's holding was the largest, worth about $995 million. In October 2026 Vanguard Capital Management filed an amended Schedule 13G reporting a 5.0% stake. See Schedule 13D vs 13G.
Who owns the most HIMS stock?
The largest reported owner of Hims & Hers Health, Inc. (HIMS) is BlackRock, Inc.. In total, 507 funds and institutions reported holding HIMS at the end of Q2 2026. See the largest owners.
Are HIMS insiders buying or selling?
In the last 12 months, HIMS insiders reported 1 open-market purchase worth $1.2M and 45 sales worth $19.3M. The latest trade was on Oct 28, 2026. See every trade.
What is the short interest in HIMS?
As of Oct 30, 2026, 51.66M HIMS shares were sold short, down 3.4% from the report before. At the average daily volume of 8.84M shares, buying them all back would take about 5.8 trading days (days to cover). See the history.
Have members of Congress traded HIMS?
Yes. 1 member of Congress reported 1 purchase and 0 sales of HIMS since Nov 17, 2024. The latest was reported on Sep 12, 2025. See the trades.
Which famous investors hold HIMS?
5 of the 50 well-known investors we track reported HIMS in their latest 13F filing, including Ken Griffin, Paul Tudor Jones, Israel Englander. The largest position is worth $14.3M. See all holders.
Executive pay
Hims & Hers Health's chief executive was paid a total of $23M for the year ended Dec 31, 2025, down 7% from $24.6M the year before. In the last 12 months, Hims & Hers Health's executives and directors bought $1.2M of stock on the open market and sold $19.3M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.